Moderna said on Monday its updated COVID-19 booster generated 'significantly higher' neutralizing antibodies against the Omicron BA.4/BA.5 subvariants than its earlier shot.
Moderna said on Monday its updated COVID-19 booster generated "significantly higher" neutralizing antibodies against the Omicron BA.4/BA.5 subvariants than its earlier shot.
The study included about 511 people ages 19 to 89 who were vaccinated, boosted with the original formulation and then boosted months later with a 50-microgram booster dose of the bivalent booster. Last month, Moderna published results for its other bivalent booster, known as mRNA-1273.214, which contains both Moderna's original vaccine as well as a vaccine targeting the original Omicron strain. That vaccine has been authorized for use in Europe. That study found that protection against BA.4 and BA.5 was also superior compared with boosting with the original vaccine.
According to the US Centers for Disease Control and Prevention, BA.5 accounts for about 30% of all new infections in the United States. As a mix of new variants rises, BQ.1.1 now represents about 24% of new infections. But the rollout of the updated boosters has been sluggish, with just 10% of people ages 5 and older getting an updated booster dose, despite 73% of that population having gotten their first two shots.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna says bivalent COVID-19 booster shot performs better against BA.5 omicron subvariantNEW: Moderna announces that a booster dose of its bivalent COVID-19 vaccine performs better against two circulating versions of the omicron variant, compared with a booster shot of its original formula.
Read more »
Florida COVID cases rising again as BQ subvariants of omicron spreadThe number of new infections grew by about 12,000 across Florida, the highest since late September.
Read more »
Moderna's Omicron shots shows better immune response than original COVID vaccineData shows that both of Moderna's Omicron-tailored shots, mRNA-1273.214 and mRNA-1273.222, produced a higher antibody response against BA.4/5 subvariants than its original shot in vaccinated and boosted adults, the company said. Moderna, however, said levels of neutralizing antibody response dropped nearly 5-fold against the emerging subvariant BQ.1.1 when compared with BA.4/5, in an analysis of about 40 participants, although the virus neutralizing activity still remained 'robust'. Rival Pfizer Inc and its German partner, BioNTech SE, said earlier this month their Omicron-tailored shot targeting the BA.4/5 subvariants produced a strong antibody response in older adults than the original shot after one month.
Read more »
Moderna says new booster increases protection against omicron subvariantsVaccine maker Moderna announced Monday that its new omicron-targeted booster shot reinforces a key line of immune defense by increasing levels of coronavirus-fighting antibodies that block BA.5.
Read more »
Moderna says updated booster stronger against omicron subvariantsModerna said on Monday its updated COVID-19 booster generated 'significantly higher' neutralizing antibodies against the Omicron BA.4/BA.5 subvariants than its earlier shot.
Read more »
Moderna says updated booster stronger against omicron subvariantsModerna said on Monday its updated COVID-19 booster generated 'significantly higher' neutralizing antibodies against the Omicron BA.4/BA.5 subvariants than its earlier shot.
Read more »